Comparison of cohorts
| End point . | Unadjusted HR (95% CI) . | Adjusted HR* (95% CI) . | ||||
|---|---|---|---|---|---|---|
| All . | AHD . | Other . | All . | AHD . | Other . | |
| Relapse-free survival | 1.27 (1.0-1.6) | 0.79 (0.5-1.2) | 1.48 (1.2-1.9) | 1.19 (0.9-1.5) | 1.10 (0.7-1.7) | 1.48 (0.9-1.6) |
| P | .03 | .26 | <.001 | .16 | .69 | .13 |
| Relapse | 1.52 (1.1-2.2) | 0.56 (0.3-1.2) | 1.97 (1.4-2.8) | 1.06 (0.7-1.6) | 0.47 (0.1-1.6) | 1.14 (0.8-1.7) |
| P | .02 | .15 | <.001 | .79 | .23 | .54 |
| Nonrelapse mortality | 1.13 (0.9-1.5) | 0.92 (0.6-1.5) | 1.22 (0.9-1.6) | 1.18 (0.9-1.6) | 1.23 (0.7-2.0) | 1.20 (0.8-1.7) |
| P | .38 | .72 | .19 | .28 | .43 | .31 |
| End point . | Unadjusted HR (95% CI) . | Adjusted HR* (95% CI) . | ||||
|---|---|---|---|---|---|---|
| All . | AHD . | Other . | All . | AHD . | Other . | |
| Relapse-free survival | 1.27 (1.0-1.6) | 0.79 (0.5-1.2) | 1.48 (1.2-1.9) | 1.19 (0.9-1.5) | 1.10 (0.7-1.7) | 1.48 (0.9-1.6) |
| P | .03 | .26 | <.001 | .16 | .69 | .13 |
| Relapse | 1.52 (1.1-2.2) | 0.56 (0.3-1.2) | 1.97 (1.4-2.8) | 1.06 (0.7-1.6) | 0.47 (0.1-1.6) | 1.14 (0.8-1.7) |
| P | .02 | .15 | <.001 | .79 | .23 | .54 |
| Nonrelapse mortality | 1.13 (0.9-1.5) | 0.92 (0.6-1.5) | 1.22 (0.9-1.6) | 1.18 (0.9-1.6) | 1.23 (0.7-2.0) | 1.20 (0.8-1.7) |
| P | .38 | .72 | .19 | .28 | .43 | .31 |
HR for secondary MDS/tAML patients (All; n=217), patients with antecedent hematologic disorders (AHD; n=55), and patients under exclusion of AHD (Other; n=162) versus de novo MDS/tAML (n=312).
HR indicates hazard ratio; CI, confidence interval; and AHD, antecedent hematologic disorder.
Adjusted for factors listed under ″Patient characteristics″ (Table 1).